Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Hypoxia-inducible factor (HIF)-1α regulates the expression of genes involved in angiogenesis, cellular energy metabolism, and cell survival during cancer development. The increased expression of HIF-1α in most solid tumors is associated with poor prognoses and therapeutic outcomes. Therefore, HIF has been recognized as an attractive target for cancer therapy, and many HIF inhibitors have been reported. AREAS COVERED: This patent survey summarizes the information about patented HIF inhibitors over the last 5 years (2011-2015). EXPERT OPINION: Although many of the HIF inhibitors reviewed in this patent survey possess inhibitory activity against cancer and HIF-related diseases, the compounds are still in the early stages of development, most likely due to the complexity of the HIF-1 pathway and their different mechanisms of action for HIF inhibition. Most cancer cells use the glycolytic pathway for energy production and HIF-1α participates deeply in the expression of several glycolytic enzymes. Therefore, a detailed study of HIF's function in cancer metabolisms may provide us an alternative strategy for further development of HIF inhibitors in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“ligase and then undergoes ubiquitin/proteasome-dependent degradation.[4,5] A hydroxylation of asparagine 803 residue in C-terminal transactivation domain (CAD) of HIF-1α by factor”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 1×
“It is well understood that most cancer cells use the glycolytic pathway for energy production rather than using the oxidative phosphorylation of mitochondria,[123] and regulation of the”
BackgroundThe Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 2×
“[113] Furthermore, HDAC inhibitor trichostatin and HSP90 inhibitor radicicol regulate HIF-1α stability under hypoxia.[113] The direct regulators of HIF-1α, such as compounds 9 (KCN) and peptidic inhibitor 28, inhibit the interaction between HIF-1α and p300 without affecting levels of the HIF-1α protein.”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 1×
“ligase and then undergoes ubiquitin/proteasome-dependent degradation.[4,5] A hydroxylation of asparagine 803 residue in C-terminal transactivation domain (CAD) of HIF-1α by factor”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
HIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · cited 1×
“metabolism, whereas loss of HIF-1 activity significantly downregulates these responses.[8] Therefore, the pro-oncogenic HIF1α protein has been suggested as an attractive target for cancer”
BackgroundHsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Passing the baton: the HIF switch
Koh, M. Y., & Powis, G. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.004 · Cited by 589 · cited 1×
“possesses similar functions to HIF-1α, including its hypoxiaresponsive activity.[117] In contrast to HIF-1α, the expression of HIF-2α is restricted to specific cells, such as endothelial cells,”
BackgroundBuckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., et al. (2014) · Nature · doi:10.1038/nature13557 · Cited by 535 · cited 1×
“been reported.[125] Therefore, further studies of HIF inhibitors in cancer metabolism are necessary in order to understand their”
BackgroundSmall molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
Wang, Y., Liu, Y., Malek, S. N., Zheng, P., & Liu, Y. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.02.006 · Cited by 410 · cited 1×
“The authors disclosed more details in a separate paper.[98] They found surprisingly that”
BackgroundWelsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
Li, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., & Park, J.-W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0074 · Cited by 160
Chun, Y.-S., Yeo, E.-J., Choi, E., Teng, C.-M., Bae, J.-M., Kim, M.-S., & Park, J.-W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00564-0 · Cited by 151
Lee, K., Kang, J. E., Park, S.-K., Jin, Y., Chung, K.-S., Kim, H.-M., Lee, K., Kang, M. R., Lee, M. K., Song, K. B., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.018 · Cited by 149 · cited 1×
“Furthermore, it has been found that LW6 induces HIF-1α degradation through a VHL-dependent proteasome pathway.[30] Further studies on the mechanism”
BackgroundSelf-citationThe role of hypoxia-inducible factor-2 in digestive system cancers
Zhao, J., Du, F., Shen, G., Zheng, F., & Xu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.565 · Cited by 122 · cited 1×
“glial cells, type II pneumocytes, cardiomyocytes, kidney fibroblasts and hepatocytes.[118] Interestingly, HIF-2α, but not HIF-”
BackgroundSignificant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
LaVallee, T. M., Burke, P. A., Swartz, G. M., Hamel, E., Agoston, G. E., Shah, J., Suwandi, L., Hanson, A. D., Fogler, W. E., Sidor, C. F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0107 · Cited by 67
Wang, L., Chen, G., Lu, X., Wang, S., Han, S., Li, Y., Ping, G., Jiang, X., Li, H., Yang, J., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.036 · Cited by 64 · cited 1×
“[40,41] LXH-SYP-7 (compound 12 in Figure 4) showed antitumor activity against a panel of cancer cells and particularly against rat glioma C6, human glioma U87, U251 and leukemia HL-60 cancer cells with IC50 values of 61.”
BackgroundEchinomycin: The first bifunctional intercalating agent in clinical trials
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985) · Investigational New Drugs · doi:10.1007/bf00170766 · Cited by 61
Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs · doi:10.1007/bf00872868 · Cited by 49
Cited by
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
HIF1α and metabolic reprogramming in inflammation
Corcoran, S. E., & O’Neill, L. A. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84431 · Cited by 776
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Sieow, J. L., Penny, H. L., Gun, S. Y., Tan, L. Q., Duan, K., Yeong, J. P. S., Pang, A., Lim, D., Toh, H. C., Lim, T. K. H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010753 · Cited by 27
Metadata
- Authors
- Ban, H. S., Uto, Y., Won, M., & Nakamura, H.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2016-02-16
- Volume
- 26
- Issue
- 3
- Pages
- 309-322
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2281813928
- Cited by
- 44
- References
- 25
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.